Start your Trading & Investing Journey with us
Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates
Accretion Nutraveda IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details
Accretion Nutraveda Limited is a nutraceutical and wellness-focused company engaged in the manufacturing and marketing of health supplements, herbal formulations, and functional nutrition products. The company earns revenue through B2B and B2C sales, supplying branded and contract-manufactured products. Its offerings are used for daily nutrition, immunity support, lifestyle health management, and preventive healthcare, catering to both domestic and export markets.
Accretion Nutraveda, an Book Built Issue, amounting to ₹
24.77 Crore,consisting entirely an Fresh Issue of
0.19 crore shares of ₹24.77 Crore,The subscription period for the Accretion Nutraveda IPO opens on January 28, 2026, and closes on January 30, 2026. The allotment is expected to be finalized on or about Monday, February 02, 2026, and the shares will be listed on the BSE SME with a tentative listing date set on or about Wednessay, February 04, 2026,
The Share Price Band of Accretion Nutraveda IPO is set at ₹122 to ₹129 per share per equity share. The Market Capitalisation of the Accretion Nutraveda at IPO price of ₹129 per equity share will be ₹93.40 Cr The lot size of the IPO is 2000 shares. Retail investors are required to invest a minimum of ₹
258,000 2 lots (2000 shares), while the minimum investment for High-Net-Worth Individuals (HNIs) is
3 lots (
3000 shares), amounting to ₹
387,000.
Sobhagya Capital Options Private Limited are the book running lead manager of the Accretion Nutraveda Ltd. while KFin Technologies Limited is the registrar for the issue,The Market Maker of the company is Sunflower Broking Private Limited
Accretion Nutraveda Limited IPO GMP Today
The Grey Market Premium of Accretion Nutraveda IPO is expected to be ₹0 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Accretion Nutraveda Limited IPO Live Subscription Status Today: Real-Time Update
As of 06:30 PM on 30 January 2026, the Accretion Nutraveda IPO live subscription status shows that the IPO subscribed 1.70 times on its Final Day of subscription period. Check the Accretion Nutraveda IPO Live Subscription Status Today at BSE.
Accretion Nutraveda Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Accretion Nutraveda IPO allotment date is Monday, February 02, 2026, Accretion Nutraveda IPO Allotment will be out on Monday, February 02, 2026, and will be live on Registrar Website from the allotment date.
KFin Technologies Limited IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Accretion Nutraveda IPO from the dropdown list of IPO
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Accretion Nutraveda Limited IPO
Accretion Nutraveda to utilise the Net Proceeds towards the following objects:
1. ₹421.66 Lakh is required for Purchase of Machineries for Automation in existing Manufacturing unit.
2. ₹803.23 Lakh is required for Purchase of Purchase of Machineries for New Manufacturing Setup.
3. ₹550.00 Lakh is required for Funding working capital requirements of our company.
4. General corporate purposes
Refer to Accretion Nutraveda Limited RHP for more details about the Company.
Accretion Nutraveda Limited Day Wise IPO GMP Trend
| GMP Date | Issue Price | Expected Listing Price | GMP | Last Updated |
|---|---|---|---|---|
| January 20, 2026 | ₹ 129 | ₹ 129 | ₹0(0.0%) | 20 January 2026; 10:46 AM |
Accretion Nutraveda IPO Details
| Market Capitalization | ₹93.40 Cr |
| IPO Date | January 28, 2026 to January 30, 2026 |
| Listing Date | February 04, 2026 |
| Face Value | ₹10 Per Share |
| Price Band | ₹122 to ₹129 |
| Issue Price | ₹129 per share |
| Employee Discount | NA |
| Lot Size | 1000 Equity Shares |
| Total Issue Size | 19,20,000 Equity Shares (aggregating to ₹24.77 Cr) |
| Fresh Issue | 19,20,000 Equity Shares (aggregating to ₹24.77 Cr) |
| Offer for Sale | NA |
| Issue Type | Book Built Issue |
| Listing At | BSE SME |
| Share holding pre issue | 53,20,000 |
| Share holding post issue | 72,40,000 |
| Rating | Avoid |
Accretion Nutraveda IPO Anchor Investors Details
| Bid Date | N/A |
| Shares Offered | N/A |
| Anchor Portion Size (In Cr.) | N/A |
| Anchor lock-in period end date for 50% shares (30 Days) | N/A |
| Anchor lock-in period end date for remaining shares (90 Days) | N/A |
Accretion Nutraveda IPO Timeline (Tentative Schedule)
| IPO Open Date | Wed, Jan 28, 2026 |
| IPO Close Date | Fri, Jan 30, 2026 |
| Basis of Allotment | Mon, Feb 2, 2026 |
| Initiation of Refunds | Tue, Feb 3, 2026 |
| Credit of Shares to Demat | Tue, Feb 3, 2026 |
| Listing Date | Wed, Feb 4, 2026 |
| Cut-off time for UPI mandate confirmation | Mon, Feb 2, 2026 |
Accretion Nutraveda IPO Reservation
| Investor Category | Shares Offered | Reservation % |
|---|---|---|
| QIB Portion | 912,000 | Not less than 50% of the Net Offer |
| Non-Institutional Investor Portion | 273,600 | Not more than 15% of the Net Issue |
| Retail Shares Offered | 638,400 | Not more than 35% of the Net Offer |
| Market Maker Portion | 96,000 | - |
Accretion Nutraveda IPO Promoter Holding
| Share Holding Pre Issue | 100.00% |
| Share Holding Post Issue | 73.48% |
Accretion Nutraveda IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹258,000 |
| Retail (Max) | 2 | 2,000 | ₹258,000 |
| S-HNI (Min) | 3 | 3,000 | ₹387,000 |
| S-HNI (Max) | 7 | 7,000 | ₹903,000 |
| B-HNI (Min) | 8 | 8,000 | ₹1,032,000 |
Accretion Nutraveda IPO Subscription Status
| Investor Category | Shares Offered | Shares Bid For | No of Times Subscribed | Last Upadeted |
|---|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 3,64,000 | 3,67,000 | 1.01x | 31 January 2026; 10:17 AM |
| Non Institutional Investors(NIIS) | 3,72,000 | 5,73,000 | 1.54x | 31 January 2026; 10:17 AM |
| Retail Individual Investors (RIIs) | 6,40,000 | 14,04,000 | 2.19x | 31 January 2026; 10:17 AM |
| Total | 13,76,000 | 23,44,000 | 1.70x | 31 January 2026; 10:18 AM |
About Accretion Nutraveda Limited
Accretion Nutraveda Limited is a nutraceutical and wellness-focused company engaged in the manufacturing and marketing of health supplements, herbal formulations, and functional nutrition products. The company earns revenue through B2B and B2C sales, supplying branded and contract-manufactured products. Its offerings are used for daily nutrition, immunity support, lifestyle health management, and preventive healthcare, catering to both domestic and export markets.
Key Clients and Manufacturing Facilities
The company caters to nutraceutical brands, wellness companies, distributors, and institutional buyers across India. Accretion Nutraveda operates its manufacturing facility in India, equipped with blending, formulation, packaging, and quality-testing infrastructure. The facility follows FSSAI and GMP-compliant processes, ensuring consistency, safety, and scalability. The integrated setup enables faster turnaround, controlled costs, and efficient order execution.
Product Portfolio and Order Book Execution
The product portfolio includes capsules, tablets, powders, syrups, and herbal supplements, covering immunity, digestion, metabolism, and general wellness. These products typically fall in the consumable and repeat-purchase category, supporting long client product life cycles. The order book is mainly short-to-medium tenure, executed through in-house manufacturing, allowing timely delivery, flexible batch sizes, and efficient capacity utilisation.
Mergers, Capex, and Expansion Plans
As per the RHP, the company has no ongoing merger or acquisition. The IPO proceeds are proposed to be utilised for capital expenditure, working capital requirements, and strengthening manufacturing capacity. Planned investments focus on equipment upgrades, product development, and operational scale-up, aimed at improving efficiency, expanding product offerings, and supporting future revenue growth.
Employees and Banker Details
As of Sep 30, 2025, the company had 18 full time employees. The Banker to the Company is HDFC Bank Limited.
MANAGEMENT & GROWTH VISION
The management team focuses on building a science-backed, scalable nutraceutical platform. Near-term growth aims include capacity expansion, wider product range, and deeper domestic penetration. Long-term targets involve brand-led growth, export market expansion, and value-added formulations. Funding for capex and expansion will be arranged through IPO proceeds, internal accruals, and efficient working capital management, while maintaining a prudent balance sheet.
INDUSTRY OVERVIEW
The company operates in the nutraceutical and dietary supplements industry, one of the fastest-growing health segments.
- Indian nutraceutical market size: ~₹60,000 crore
- Expected CAGR (India): ~15–18%
- Global nutraceutical market size: ~USD 450 billion
- Global growth rate: ~8–9% CAGR
Growth is driven by rising health awareness, preventive healthcare demand, ageing population, and lifestyle-related diseases. India is emerging as a manufacturing and formulation hub, while global leaders include Amway, Herbalife, and Nestlé Health Science.
KEY RISK FACTORS
- Regulatory Compliance Risk
The business is highly regulated under FSSAI and other health laws. Any non-compliance or change in regulations may impact product approvals, timelines, or operational costs. - Dependence on Key Raw Materials
The company relies on specific herbal and nutritional ingredients. Price volatility or supply disruptions may affect margins and production schedules. - High Industry Competition
The nutraceutical industry is fragmented and competitive, with both domestic and global players, which may pressure pricing and market share. - Limited Brand Visibility
A significant portion of revenue comes from contract manufacturing, limiting direct brand recall and increasing dependence on third-party clients. - Working Capital Intensive Operations
Inventory holding, receivables, and production cycles require continuous working capital, which may impact cash flows during rapid growth phases. - Consumer Preference Changes
Shifts in consumer trends, formulation preferences, or health awareness may affect demand for existing product categories.
KEY STRENGTHS, MOAT & OPPORTUNITIES
- Integrated Manufacturing Capability
End-to-end in-house manufacturing ensures quality control, cost efficiency, and faster execution, creating a strong operational moat. - Wide Product Portfolio
Presence across multiple dosage forms and wellness categories reduces dependence on a single product line. - High-Growth Industry Exposure
Operating in a fast-growing nutraceutical market provides long-term structural growth opportunities. - Scalable Business Model
The asset-light expansion approach and modular manufacturing enable scalable capacity growth with controlled capital costs. - Growing Preventive Healthcare Demand
Rising focus on immunity, fitness, and lifestyle health creates repeat demand and long-term customer stickiness. - Export and Private Label Opportunity
Increasing demand for Indian-manufactured nutraceuticals globally offers expansion into export and private-label segments.
Accretion Nutraveda Limited Financial Information (Restated Consolidated)
Amount in (₹ in Lakhs)
| Period Ended | Sep 30, 2025 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Reserve of Surplus | 294.65 | 486.17 | 72.49 | -9.69 |
| Total Assets | 1,634.94 | 1,086.22 | 463.88 | 406.02 |
| Total Borrowings | 442.98 | 385.87 | 217.36 | 197.33 |
| Fixed Assets | 186.39 | 201.63 | 128.43 | 148.90 |
| Cash | 0.35 | 1.54 | 11.90 | 8.61 |
| Cash flow from operating activities | -88.72 | -221.27 | 23.02 | 68.13 |
| Cash flows from investing activities | -1.89 | -87.20 | -15.83 | -0.55 |
| Cash flow from financing activities | 89.42 | 298.12 | -3.91 | -63.40 |
| Net Borrowing | 442.63 | 384.33 | 205.46 | 188.72 |
| Revenue | 1,406.55 | 1,605.55 | 519.68 | 307.14 |
| EBITDA | 328.55 | 364.66 | 120.60 | 59.12 |
| PAT | 233.28 | 261.28 | 82.19 | 28.06 |
| PAT Margin | 16.59% | 16.27% | 15.82% | 9.14% |
| EPS | 4.73 | 71.91 | 22.83 | 7.79 |
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on Cap Price Post Issue Data, given in FINANCIAL EXPRESS.
Key Performance Indicator
| KPI | Values |
|---|---|
| EPS Pre IPO (Rs.) | 71.91 |
| EPS Post IPO (Rs.) | 3.61 |
| Adjusted 12M EPS Post IPO (Rs.) | 6.44 |
| P/E Pre IPO | 1.79 |
| P/E Post IPO | 35.75 |
| Adjusted 12M P/E Post IPO | 20.02 |
| ROE | 81.22% |
| ROCE | 36.98% |
| P/BV | 8.76 |
| Debt/Equity | 0.72 |
| RoNW | 48.85% |
| EBITDA Margin | 22.79% |
| PAT Margin | 16.27% |
Accretion Nutraveda Limited IPO Peer Comparison
| Company Name | EPS | P/E (x) | ROE | ROCE | P/BV | Debt/Equity | RoNW (%) |
|---|---|---|---|---|---|---|---|
| Accretion Nutraveda | 3.61 | 35.75 | 81.22% | 36.98% | 8.76 | 0.72 | 48.85% |
| Influx Healthtech | 7.31 | 25.93 | 45.4 % | 60.2 % | 37.80 | 0.00 | 36.72% |
| Walpar Nutritions | 1.80 | 23.94 | 15.1 % | 16.1 % | 3.31 | 0.48 | 11.27% |
Accretion Nutraveda Limited Contact Details
Accretion Nutraveda Limited
Phone: +91- 9904366177
Email: compliance@accretionnutraveda.com
Website: https://accretionnutraveda.com/
Accretion Nutraveda IPO Registrar and Lead Manager(s)
KFin Technologies Limited
Phone: +91 40 6716 2222
Email: apl.ipo@kfintech.com
Website: http://www.kfintech.com/
Sobhagya Capital Options Private Limited
Phone:+91 7836066001
Email: cs@sobhagyacap.com
Website: https://www.sobhagyacapital.com/contact-us/
Accretion Nutraveda IPO Review
Accretion Nutraveda Limited is a nutraceutical and wellness-focused company engaged in the manufacturing and marketing of health supplements, herbal formulations, and functional nutrition products. The company earns revenue through B2B and B2C sales, supplying branded and contract-manufactured products. Its offerings are used for daily nutrition, immunity support, lifestyle health management, and preventive healthcare, catering to both domestic and export markets.
The Company is led by Promoter, i.e.,MR. MAYUR POPATLAL SOJITRA, MR. ANKURKUMAR SHANTILAL PATEL, MR. PARASKUMAR VINUBHAI PARMAR, MR. HARDIK MUKUNDBHAI PRAJAPATI, MR. HARSHAD NANUBHAI RATHOD & MR. VIVEK ASHOK KUMAR PATEL
The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,406.55 Lakh, ₹ 1,605.55 Lakh, ₹ 519.68 Lakh, and ₹ 307.14 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 328.55 Lakh, ₹ 364.66 Lakh, ₹ 120.60 Lakh, and ₹ 59.12 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 233.28 Lakh, ₹ 261.28 Lakh, ₹ 82.19 Lakh, and ₹ 28.06 Lakh, respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹ 71.91 and post-issue EPS of ₹ 3.61 for FY25. The pre-issue P/E ratio is 1.79x,while the post-issue P/E ratio is 35.75x against the Industry P/E ratio is 45.14x The company's ROE for FY25 is 81.22% and RoNW is 48.85% The Annualised EPS is ₹ 6.44x and P/E is ₹ 20.02x, These metrics suggest that the IPO is Fully priced.
The Grey Market Premium (GMP) of Accretion Nutraveda showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Accretion Nutraveda Limited. IPO for Listing gain or Long Term Purposes.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. We also use Artificial Intelligence (AI) tools to enhance the efficiency and quality of our research services, including data retrieval, analysis, and report summarization. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit Legal our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.
Services
Equity Investment with CA Abhay
Equity Trading with CA Abhay
Option Trading with CA Abhay
Stock Market Masterclass
© 2022 CA Abhay Varn. All Rights Reserved Abhayvarn.com
